BioSpace News Archive

COSMAX Group has succeeded in developing and commercializing a technology that dramatically increased the intestinal survival rate of lactic acid bacteria.

CAR T Cell Therapies Driving New Era Of Combination Cancer Therapies Says Kuick Research.

Kuick Research Report Gives Insight On 600 CAR T Cell Therapies In Clinical Trials.

Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic designed to disrupt cancer’s energy metabolism and improve quality of life for patients, today announced the publication of positive data from a preclinical study evaluating GP-2250 for the treatment of pancreatic neuroendocrine carcinoma.

The Biochips industry report emphasizes the current and upcoming market revenue growth opportunities and trends.

Amytrx and Amarex Clinical Research, LLC, an NSF company, today announced they are initiating the Phase II clinical trial on atopic dermatitis (AD) using Amytrx’s therapeutic AMTX-100 CF3.

Tiziana Life Sciences announces an interview with Chief Executive Officer and Chief Scientific Officer Kunwar Shailubhai, PhD and Proactive Investors discussing the positive clinical results from the second patient with Secondary Progressive Multiple Sclerosis in the ongoing study as part of an expanded access program at the Brigham and Women’s Hospital, Boston, MA.

Tiziana Life Sciences PLC announced positive clinical results for its second secondary progressive multiple sclerosis patient in a June 8th press release.

Mnemo Therapeutics announced a publication in Cell Reports that demonstrates peptides derived from transposable elements – mobile regions of DNA that move to other areas of the genome – may represent cancer-specific targets for immunotherapy.

NEXT Bio Research Services LLC, dba NEXT Molecular Analytics is pleased to announce that the New York State Department of Health has accredited the Company’s L-Asparaginase enzyme activity assay platform.